Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curasight ASXSAT:CURAS -6.27%24 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates XSAT:CURAS with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 841 Biotechnology companies, Curasight AS ranks worse than 118905.95% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Curasight AS's Revenue for the
three
months ended in Mar. 2026 was kr0.00 Mil. Curasight AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Curasight AS (XSAT:CURAS) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Curasight AS Receivables Turnover Related Terms
Curasight AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Curasight AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CURAS vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Curasight AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curasight AS Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curasight AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Curasight AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curasight AS (XSAT:CURAS) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Curasight AS and its competitors. According to the industry distribution chart, Curasight AS ranks #999999 out of 841 companies in the Biotechnology industry.
Is Curasight AS's Receivables Turnover too high?
Curasight AS's current Receivables Turnover is 0.00. Based on the distribution chart, Curasight AS ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Curasight AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Curasight AS's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Curasight AS ranks #999999 out of 841 companies for Receivables Turnover. This places Curasight AS in the lower half of its industry. The industry median Receivables Turnover is 5.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Curasight AS and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curasight AS's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curasight AS stock overvalued right now?
Curasight AS (XSAT:CURAS) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Curasight AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Curasight AS (XSAT:CURAS), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
24GF Score
Get the complete analysis for XSAT:CURAS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CURAS has been successfully added to your 
